M
Masaru Taniguchi
Researcher at Hokkaido University
Publications - 7
Citations - 716
Masaru Taniguchi is an academic researcher from Hokkaido University. The author has contributed to research in topics: Encephalomyelitis & Systemic scleroderma. The author has an hindex of 5, co-authored 7 publications receiving 700 citations.
Papers
More filters
Journal ArticleDOI
The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
Hidemitsu Kitamura,Kenji Iwakabe,Takashi Yahata,Shin-Ichiro Nishimura,Akio Ohta,Yasushi Ohmi,Marimo Sato,Kazuyoshi Takeda,Ko Okumura,Luc Van Kaer,Tetsu Kawano,Masaru Taniguchi,Takashi Nishimura +12 more
TL;DR: Findings indicate an important role for DC-produced IL-12 in the activation of NKT cells by α-GalCer and suggest that N KT cells may be able to condition DCs for subsequent immune responses and suggest a novel approach for immunotherapy of cancer.
Patent
Nkt cell activators containing alpha-glycosylceramides
TL;DR: NKT cell activators, remedies for autoimmune diseases (for example, systemic erythematodes, systemic scleroderma, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes) and abortifacients as discussed by the authors.
Patent
NKT CELL ACTIVATORS CONTAINING α-GLYCOSYLCERAMIDES
TL;DR: NKT cell activators, remedies for autoimmune diseases (for example, systemic erythematodes, systemic scleroderma, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes) and abortifacients.
Patent
Use of a-glycosylceramides for the manufacture of a therapeutic agent for autoimmune diseases
TL;DR: NKT cell activators, remedies for autoimmune diseases (for example, systemic erythematodes, systemic scleroderma, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes) and abortifacients.
Patent
Nkt cell-activating agents containing .alpha.-glycosylceramides
TL;DR: In this paper, a NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients were provided.